KBI-BIOPHARMA
KBI Biopharma SA (KBI) and Selexis SA, both JSR Life Sciences companies, held a joint ribbon-cutting ceremony yesterday at their new state-of-the-art facility in Geneva, Switzerland. Designed to directly serve the increased demand for biopharmaceutical drug development and manufacturing in Europe, the facility will support an integrated, end-to-end process of Selexis’ cell line development (CLD) services along with KBI’s contract development and manufacturing services for industry clients throughout the immediate region and beyond.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220706005082/en/
As demand for innovative biologics and effective biosimilars to treat cancer, infectious diseases, and autoimmune diseases continue to rise in Europe and around the world, developing and manufacturing these and other therapeutics, remains complex and time-consuming. By co-locating in one facility, KBI and Selexis will deliver trusted, streamlined, and cost-effective solutions to help clients confidently advance their investigational therapies.
“The opening of our Geneva facility last month was a major milestone for KBI and Selexis, and we are excited to come together today and commemorate this great achievement,” said Mark W. Womack, CEO of KBI and Selexis. “KBI and Selexis have a long history of success together. Our collaboration has accelerated more than 60 drug development programs in Europe and worldwide. Integrating Selexis’ world-renowned CLD services with KBI’s process development innovation and excellence, as well as clinical and commercial manufacturing experience provides our clients with seamless, cost-effective, and reliable development and manufacturing for their products. Our aim has always been to help our clients bring novel and effective therapies to the clinic and the market faster. This facility will help advance that mission.”
The ~94,000 square-foot facility will house new laboratories to support Selexis’ unique technical cell line workflows and KBI’s process development and cGMP manufacturing and quality control with a suite of analytical testing laboratories and cGMP single-use manufacturing trains. The expansion will generate over 300 positions in development, operations, and quality assurance. The ribbon-cutting, held on July 5, was attended by the following:
- Luca Bolliger, VP of the Swiss Biotech Association and President of the Swiss Biotech Success Stories Jury
- Mario Rodriguez, Mayor of Plan-les-Ouates
- Fabienne Fischer, State Councilor - Member of the Geneva government, Head of the economy and employment department (DEE)
“I am delighted with the development of KBI and Selexis' activities in Geneva, which contributes to the development of the life sciences sector in Geneva and reinforces our local ecosystem,” said Councilor Fischer. “It also demonstrates the potential and attractiveness of our region.”
About KBI Biopharma, Inc.
KBI Biopharma SA is a wholly-owned subsidiary of KBI Biopharma, Inc., and a JSR Life Sciences company. KBI Biopharma is a leading global contract development and manufacturing organization (CDMO) providing fully integrated, accelerated drug development and biologics manufacturing services and expertise to life science companies. With each of its 500+ client partners, KBI works closely to personalize and accelerate drug development programs. Built upon a foundation of world-class analytics capabilities and extensive scientific and technical expertise, KBI delivers robust process development and clinical and commercial cGMP manufacturing services for mammalian, microbial, and cell therapy programs. Recognized for quality manufacturing, KBI helps clients advance drug candidates into the clinic and beyond. KBI serves its global clients with multiple locations in Europe and the USA. www.kbibiopharma.com
About Selexis SA
Selexis SA, a JSR Life Sciences company, is the global leader in cell line development with best-in-class modular technology and highly specialized solutions that enable the life sciences industry to rapidly discover, develop and commercialize innovative medicines and vaccines. Our global client partners have utilized Selexis technologies to advance more than 160 drug candidates in preclinical and clinical development and manufacture ten commercial products. As part of a comprehensive drug development process, the Company’s technologies shorten development timelines and reduce manufacturing risks. More information is available at www.selexis.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20220706005082/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Corpay Cross-Border Named the Official FX Partner for BLAST12.11.2025 14:30:00 CET | Press release
Providing access to currency risk management and cross-border payments solutions Corpay, Inc.* (NYSE: CPAY), a global leader in corporate payments, today announced that its Cross-Border business has entered into a multi-year agreement with the BLAST, a global competitive entertainment company with a mission to bring mega entertainment to the world, taking esports, gaming and other new competitive formats to the next level. Under the agreement, Corpay will serve as their Official Foreign Exchange Partner. Through this partnership, BLAST will be able to use Corpay Cross-Border’s innovative solutions to help mitigate foreign exchange exposure in their daily operations. They’ll also benefit from Corpay’s award-winning platform, which allows for seamless global payment management from a single point of access. “Corpay is thrilled to be named the Official FX Partner for BLAST, a true pioneer in the world of esports,” said Brad Loder, Chief Marketing Officer, Corpay Cross-Border Solutions. “T
De' Longhi S.p.A. - Another Record Quarter: Revenues at €877 Million, up 11.5% at Constant Currency, and Adjusted EBITDA Margin at 17.0%. Guidance Raised12.11.2025 14:29:00 CET | Press release
The leadership position in the home coffee market allows the Group to achieve significant growth, thanks to the structural trend of espresso’s expansion and premiumization, further strengthened by the strong expansion of the professional division Approved by the Board of Directors of De' Longhi S.p.A. the consolidated results for the nine months of 2025. In the nine months the Group achieved: revenues for € 2,461.4 million, up by 10.4% with respect to 2024 (11.7% at constant currency); an adjusted Ebitda of € 389.5 million, equal to 15.8% on revenues (vs. 15.1% last year); a net income pertaining to the Group equal to € 187.6 million (+8.0% with respect to last year); a positive net financial position equal to € 308.7 million. In the third quarter the Group achieved: revenues for € 877.2 million, up by 8.9% with respect to 2024 (11.5% at constant currency); an adjusted Ebitda of € 148.8 million, or 17.0% on revenues (vs. 16.3% last year) a net income pertaining to the Group amounting t
World Leaders and Industry Icons Unite Under BRIDGE Alliance to Empower the Future of Media, Entertainment and Content12.11.2025 14:11:00 CET | Press release
A new international alliance of policymakers, creative leaders, and innovators has come together under the banner of BRIDGE Alliance to advance inclusivity, investment, and sustainable development in the global media, entertainment and content economy. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251112707768/en/ World leaders and industry icons unite under BRIDGE Alliance to empower the future of media, entertainment and content (Photo: AETOSWire) Headquartered in the UAE, BRIDGE Alliance stands as a first-of-its-kind global body chaired by H.E. Abdulla bin Mohammed bin Butti Al Hamed. It brings together an influential board comprising former heads of state, global leaders, policymakers, and CEOs from the media, communication, technology, finance, and creative sectors. The founding board includes HRH Princess Lamia bint Majed Al Saud, CEO of Rotana Media Group and Secretary-General of Alwaleed Philanthropies; H.E. Macky S
Sutherland and Celona Launch AI-Enabled Private 5G and Autonomous Network Solution for Enterprises and Service Providers Globally12.11.2025 14:00:00 CET | Press release
Self-managing 5G solution reduces complexity, improves uptime, and accelerates transformation in mission-critical environments. In a move set to redefine how enterprises and service providers manage mission-critical connectivity, Sutherland, a global leader in business and digital transformation, today announced the launch of an AI-enabled Private 5G and Autonomous Network solution in collaboration with Celona, the Silicon Valley innovator that pioneered the 5G LAN architecture. This end-to-end offering brings together Sutherland’s Agentic Service Management Orchestration (SMO) platform and suite of AI-enabled xApps and rApps with Celona’s next-generation private 5G infrastructure. The result is a self-managing, intent-based network that dramatically reduces human intervention while increasing performance, resilience, and sustainability across enterprise and telecom environments. “Enterprises no longer want to manage networks — they want networks that manage themselves,” said Sriram Pa
Vasion Welcomes Cindy White Cybersecurity Expert and Former Microsoft Marketing Leader as Chief Marketing Officer12.11.2025 14:00:00 CET | Press release
Vasion, a leader in serverless printing and AI-enabled automation, today announced the appointment of Cindy White as Chief Marketing Officer, effective October 2025. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251112275154/en/ Vasion CMO Cindy White brings more than 25 years of experience leading high performance marketing teams at global technology companies. As organizations accelerate their transition to the cloud, Vasion is redefining what’s possible in the print and process automation landscape. Vasion enables tens of thousands of global customers to start with intelligent print and move to print intelligence, removing friction, cost, and risk from critical print environments, empowering them to move faster with secure, cloud-native, AI-based solutions. “Cindy’s global expertise and proven ability to scale marketing organizations across both direct and partner-driven go-to-markets will be instrumental as Vasion conti
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom